Evidence map›Paper›PMID 29033371›Full record

ArticleEBioMedicine2017

A Small Molecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses Colorectal Cancer Growth In Vitro and In Vivo.

Seung Ho Shin, Do Young Lim, Kanamata Reddy, Margarita Malakhova, Fangfang Liu, Ting Wang, Mengqiu Song, Hanyong Chen, Ki Beom Bae, Joohyun Ryu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Potentials of N-Acyl Hydrazones Against Colorectal Cancer: A Mini Review.Anti-cancer agents in medicinal chemistry · 2025
    Review
  7. Role of bestatin as a treatment for periodontitis.Frontiers in dental medicine · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. TCOF1 promotes the colorectal cancer progression by stabilizing β-catenin.Medical oncology (Northwood, London, England) · 2023
    Article
  12. Emerging Direct Targeting β-Catenin Agents.Molecules (Basel, Switzerland) · 2022
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Moonlighting at the Poles: Non-Canonical Functions of Centrosomes.Frontiers in cell and developmental biology · 2022
    Review
  18. Article
  19. Natural products targeting cancer cell dependency.The Journal of antibiotics · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Seung Ho ShinThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA; Program in Bioinformatics and Computational Biology, University of Minnesota, Minneapolis, MN 55455, USA.
Do Young LimThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Kanamata ReddyThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Margarita MalakhovaThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Fangfang LiuThe China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China; The Pathophysiology Department, The School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Ting WangThe China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Mengqiu SongThe China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China; The Pathophysiology Department, The School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.
Hanyong ChenThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Ki Beom BaeThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Joohyun RyuThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Kangdong LiuThe China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China; The Pathophysiology Department, The School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou, China; The Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou, Henan, China.
Mee-Hyun LeeThe China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
Ann M BodeThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA; Program in Bioinformatics and Computational Biology, University of Minnesota, Minneapolis, MN 55455, USA.
Zigang DongThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA; Program in Bioinformatics and Computational Biology, University of Minnesota, Minneapolis, MN 55455, USA; The China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China; The Pathophysiology Department, The School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou, China; The Affiliated Cancer Hospital, Zhengzhou University, Zhengzhou, Henan, China. Electronic address: zgdong@hi.umn.edu.
Hormel (United States) · USChina-US (Henan) Hormel Cancer Institute · CNUniversity of Minnesota · USZhengzhou University · CN

Funding

Chemoprevention of colon cancer by targeting the Wnt/beta-catenin pathwayR01CA187027 · NCI · UNIVERSITY OF MINNESOTA · PI KANG, NINGLING, ROH, EUNMIRI · 2015 to 2019
$1.7M
NCI NIH HHS R01 CA187027
6 · The paper itself

Abstract

Colorectal cancer is associated with aberrant activation of the Wnt pathway. β-Catenin plays essential roles in the Wnt pathway by interacting with T-cell factor 4 (TCF4) to transcribe oncogenes. We synthesized a small molecule, referred to as HI-B1, and evaluated signaling changes and biological consequences induced by the compound. HI-B1 inhibited β-catenin/TCF4 luciferase activity and preferentially caused apoptosis of cancer cells in which the survival is dependent on β-catenin. The formation of the β-catenin/TCF4 complex was disrupted by HI-B1 due to the direct interaction of HI-B1 with β-catenin. Colon cancer patient-derived xenograft (PDX) studies showed that a tumor with higher levels of β-catenin expression was more sensitive to HI-B1 treatment, compared to a tumor with lower expression levels of β-catenin. The different sensitivities of PDX tumors to HI-B1 were dependent on the β-catenin expression level and potentially could be further exploited for biomarker development and therapeutic applications against colon cancer.

Indexed as

AnimalsApoptosisbeta CateninCell Line, TumorCell ProliferationColorectal NeoplasmsGene Expression Regulation, NeoplasticHumansMiceMultiprotein ComplexesSmall Molecule LibrariesTranscription Factor 4Wnt Signaling PathwayXenograft Model Antitumor Assaysbeta CateninCTNNB1 protein, humanMultiprotein ComplexesSmall Molecule LibrariesTCF4 protein, humanTranscription Factor 4Colorectal cancerHI-B1Patient-derived xenograftPrecision medicineSmall molecule inhibitorβ-catenin

Identifiers

PMID29033371
PMCPMC5704052
OpenAlexW2756675167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.